# A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

> **NCT00637390** · PHASE1 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00637390
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Genzyme will no longer supply the study drug for this trial as it does not believe the study will not fully enroll within an appropriate time frame.
- **Last updated:** 2016-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637390, "A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00637390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*